Decision

Advertising investigations: November 2019

Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 24 December 2019

Documents

November 2019 - Advisory board for Crysvita (burosumab) by Kyowa Kirin Limited

MS Word Document, 363 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

November 2019 - Clinics advertising botulinum toxin products

MS Word Document, 23.7 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

November 2019 - Websites offering medicinal treatment services

MS Word Document, 26.3 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Contact advertising@mhra.gov.uk if you have concerns with the advertising of medicines or write to:

Advertising Standards Unit,
10 South Colonnade
Canary Wharf
London
E14 4PU

Alternatively, contact the pharmaceutical self-regulatory bodies, the Proprietary Association of Great Britain (PAGB) for advertising for over the counter medicines, or the Prescription Medicines Code of Practice Authority (PMCPA) for advertisements to health professionals for prescription medicines.

See the Blue Guide for guidance on how medicines should be promoted or advertised in the UK.

Published 24 December 2019